ATLANTA, May 23 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will present at the Friedman, Billings, Ramsey & Co. 2006 Growth Investor Conference on Wednesday, May 31, 2006 at 1:30 p.m. ET from the Grand Hyatt Hotel in New York City. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex, Inc. will provide an update on the company.
A live audio webcast of the presentation will be available on the “Investors” section of the company’s website at http://www.inhibitex.com. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery and development of antibody-based products for the prevention and treatment of serious, life- threatening infections. All of the company’s drug development programs are based on its proprietary MSCRAMM(R) protein platform. MSCRAMM proteins are located on the surface of pathogenic organisms and are responsible for the initiation and spread of infections. The company’s clinical candidates are Veronate(R) and Aurexis(R), for which the company has retained all worldwide rights. The company’s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the company, please visit http://www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Laura Perry (Investors) Chief Financial Officer Stern Investor Relations, Inc. (678) 746-1136 (212) 362-1200 rplumb@inhib laura@sternir.com
Inhibitex, Inc.
CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Laura Perry ofStern Investor Relations, Inc. for Inhibitex, Inc., +1-212-362-1200, orlaura@sternir.com
Web site: http://www.inhibitex.com//
